Webinars

Discover How Targeted Radiotherapy Induced Toxicity May Be Identified Using Imaging

Jones Nauseef M.D., PhD
Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
Tim Perk, PhD
VP of Research, AIQ Solutions

The current standards of quantifying treatment response for oncology studies such as RECIST and blood tests neglect the impact of intra-patient heterogeneity.

Artificial intelligence technologies continue to gain traction by delivering in depth assessments of treatment response and relationship to adverse event burden. Weill Cornell Medicine applied AIQ Solutions’ technology to patients with prostate cancer treated with prostate-specific membrane antigen (PSMA)-targeted radiotherapy (177Lu-PSMA-617). Automated quantification of 68Ga-PSMA PET tracer uptake was found to be associated with treatment response and adverse events.

Join this webinar to learn how AI-assisted analysis of radiological scans enhances understanding of treatment efficacy and adverse effect burden through spatiotemporal patient response assessments

How to Use Novel Imaging Analysis Technology to Redefine Oncology Treatment

Elisabeth I. Heath, MD, FACP
Associate Center Director of Translational Sciences of Karmanos Cancer Institute, Wayne State University
Katharina Modelska, MD, PhD
Vice President, Clinical Development, FibroGen
Tim Perk, PhD
VP of Research, AIQ Solutions

Karmanos Cancer Institute and Pfizer together with AIQ address how they were able to decrease the time and cost of assessing patient response to immunotherapy assets, including efficacy and toxicity risk, using an imaging analysis software platform. They present a discussion on a novel imaging analysis technology collaboration redefining intra-patient treatment response heterogeneity and how that heterogeneity impacts patient clinical response.
This collaboration was recently included in the Best of Journal of Clinical Oncology 2021 Genitourinary Cancer Edition. You will hear directly from the researchers and technologists that made this collaboration possible and learn:

  • How interlesion response heterogeneity can impact clinical progression for patients
  • How quantitative imaging can improve treatment response assessment
  • How to use imaging analytics for early and rapid determination of pharmacodynamic effects with a small cohort of patients
Discovering Amyloidosis: How AI Imaging Application Shed Light on Rare Disease

Jonathan Wall, PhD
Professor and Assistant Dean for Research, University of Tennessee
Amy Weisman, PhD
Lead Project Scientist, AIQ Solutions

Systemic amyloidosis is a rare disease resulting in organ malfunction from build-up of the protein amyloid. Detection and quantification of amyloid burden in the body is an unmet clinical need with approximately 80% of patients undiagnosed.

Dr. Jonathan Wall of the University of Tennessee, together with AIQ Solutions, used an AI-driven, fully automated 3D segmentation and quantitation of a novel radiotracer to quantify amyloid burden in patients’ hearts and other organs.

This automated approach to image analysis could be an invaluable tool for novice readers, especially to quantify disease burden over time without introducing reader bias. This case study was in the rare disease amyloidosis, but this method has broad implications for meeting unmet needs in metastatic cancers and other complex diseases.

Harnessing the Power of Advanced Imaging to Elevate Treatment Response Assessments & Optimize Trial Outcomes

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma
Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery
Eric Horler
President and Chief Executive Officer, AIQ Solutions

Advanced medical imaging is fueling new opportunities to improve understanding and quantification of cancer treatment response. Until now, the use of imaging (e.g.CT, PET, SPECT) in clinical trials has been limited to measuring a subset of lesions (usually 3-5) per scan and generalizing the results to the total disease. It has been demonstrated in published studies; however, that resistance in less than 10% of lesions can drive a poor overall clinical outcome. To comprehensively quantify treatment response, all lesions should be measured which is clinically infeasible without automation.

Join us for this 60-minute webinar as we address the above challenges and delve inside recent clinical research applications using novel technology to automatically detect and measure lesion-wise response over multiple scans.

Learning Objectives:

  • Detecting and quantifying lesions of change in patients with a variety of metastatic cancers
  • Analyzing the importance of including heterogeneity in clinical studies and treatment assessments, the gaps it creates when not taken into account, and how this problem is handled now
  • Discussing ways to properly utilize additional information obtainable from imaging
  • Looking into the practicality of manually assessing all lesions in patients
  • Addressing the need to compare lesions identified on different imaging modalities
Computational Approaches to the Optimization of Dose and Schedule: Computational Science in Immuno-Oncology

Presenter: Robert Jeraj, PhD – University of Wisconsin-Madison
Moderator: Matthew Reilley, MD – University of Virginia

SITC-NCI Computational Immuno-oncology Webinar Series, click here to view the webinar on demand

⮐ Back to Resources Main

Information on this page is intended for research use only. Not all applications and/or claims listed are currently cleared for use in treatment of patients. TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444.

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

This will close in 40 seconds

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.

This will close in 40 seconds

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September 2018. He has led AIQ through two rounds of equity financing, team construction, product commercialization, and international expansion. Before joining the AIQ team, Eric was President and CEO of Swallow Solutions LLC, a medical device start-up with both therapeutic devices and functional beverages for dysphagia patients. Before that, Eric was General Manager, Premium Anesthesia and Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a $220 million global business and a large team spread over three continents. He has also held a series of marketing and business development roles at Baxter Healthcare, including Director of Renal Products and Services for the Latin America region. Eric has a B.S. in Chemical Engineering from Rice University and both an MBA and Master of Engineering Management degrees from the Kellogg School of Business. He lives in Madison with his wife and two children.

This will close in 40 seconds

Information on this page is intended for research use only. Applications and/or claims listed are not currently cleared for use in treatment of patients.